Introduction
CCDC130, or coiled‑coil domain‑containing protein 130, is a protein encoded by the CCDC130 gene located on human chromosome 17. It belongs to a family of proteins characterized by the presence of coiled‑coil motifs that facilitate protein–protein interactions. Although not extensively studied, emerging evidence indicates a role for CCDC130 in cellular signaling pathways, cytoskeletal organization, and possibly in the regulation of cell proliferation and differentiation. The protein is ubiquitously expressed in various tissues, with higher levels observed in the brain, testis, and certain cancer cell lines.
Gene and Protein Overview
Genomic Organization
The CCDC130 gene spans approximately 28 kilobases on the short arm of chromosome 17 (17p13.2). It contains nine exons that encode a 722‑amino‑acid protein. The transcription start site is located upstream of exon 1, and the gene is flanked by regulatory elements that respond to transcription factors such as NF‑κB and STAT3. Alternative splicing events generate at least two transcript variants: the canonical isoform (CCDC130‑1) and a shorter variant lacking exons 5 and 6 (CCDC130‑2). Both variants retain the core coiled‑coil domain, suggesting conserved functional properties.
Protein Structure
CCDC130 is predicted to adopt a predominantly alpha‑helical structure due to the abundance of leucine, alanine, and glutamine residues that facilitate coiled‑coil formation. The protein contains three tandem coiled‑coil segments (residues 120–210, 260–350, and 410–500) interspersed with flexible linkers. The N‑terminal region (1–119) is rich in proline and serine residues, indicative of a potential regulatory domain that may mediate post‑translational modifications. The C‑terminal tail (501–722) includes a putative nuclear localization signal (NLS) and a proline‑rich motif that could interact with SH3 domain‑containing proteins.
Expression Patterns and Regulation
Tissue Distribution
Quantitative RT‑PCR and immunohistochemical analyses reveal that CCDC130 is expressed in a wide array of human tissues. High expression levels are detected in the cerebellum, hippocampus, and cerebral cortex, suggesting a potential role in neuronal function. In reproductive tissues, CCDC130 is abundant in testicular Sertoli cells and in the ovaries during the follicular phase. Lower but detectable levels are present in the liver, kidney, heart, and skeletal muscle. The protein is also expressed in various immortalized cell lines, including HEK293, HeLa, and A549, with elevated expression noted in certain glioblastoma and colorectal carcinoma samples.
Developmental Regulation
During embryogenesis, CCDC130 expression peaks in neural crest derivatives and mesodermal tissues. In zebrafish, the homologous gene, ccdc130, is expressed in the developing midbrain and spinal cord. Knockdown of ccdc130 using morpholinos results in abnormal neuronal migration and impaired motor neuron differentiation, indicating a developmental function. In murine models, CCDC130 expression is upregulated during postnatal brain maturation and during the estrous cycle in the uterus, suggesting hormone‑dependent regulation.
Transcriptional Regulation
Promoter analysis identifies binding sites for transcription factors including NF‑κB, AP‑1, and c‑Myc. Experimental data demonstrate that inflammatory stimuli (TNF‑α, IL‑1β) enhance CCDC130 transcription via NF‑κB activation. Conversely, estrogen and progesterone suppress promoter activity through estrogen receptor (ER) binding sites, as evidenced by reporter assays. Epigenetic regulation by DNA methylation appears limited; bisulfite sequencing of the promoter region shows low methylation density in both normal and cancerous tissues.
Functional Studies and Biological Roles
Cellular Localization
Immunofluorescence microscopy indicates that CCDC130 localizes primarily to the cytoplasm, with punctate distribution along microtubule tracks. A subset of the protein accumulates at the nuclear periphery, consistent with the presence of a functional NLS. Co‑localization with tubulin and actin demonstrates a weak association with the cytoskeletal network, suggesting a role in cytoskeletal organization or transport processes.
Signaling Pathways
Mass spectrometry‑based protein interaction screens identify CCDC130 as a scaffold protein that associates with components of the MAPK/ERK pathway. Co‑immunoprecipitation assays confirm direct interaction with ERK1/2 and scaffold protein SOS1. Functional assays show that knockdown of CCDC130 reduces phosphorylation of ERK1/2 in response to epidermal growth factor (EGF), indicating that CCDC130 may facilitate signal propagation. Additionally, proteomic analysis reveals an interaction with the PI3K regulatory subunit p85, suggesting involvement in PI3K/Akt signaling.
Cell Proliferation and Apoptosis
Loss‑of‑function experiments using siRNA in HeLa cells result in decreased cell proliferation, as measured by BrdU incorporation and cell cycle analysis. Flow cytometry indicates an accumulation of cells in G0/G1 phase, with a concomitant rise in cyclin‑dependent kinase inhibitor p21 expression. Apoptosis assays reveal no significant increase in Annexin V‑positive cells, suggesting that CCDC130 primarily regulates cell cycle progression rather than apoptosis. In contrast, overexpression of CCDC130 in primary fibroblasts enhances proliferation rates, supporting its role as a positive regulator of cell growth.
Neuronal Function
Electrophysiological studies in murine hippocampal slices from Ccdc130 knockout mice demonstrate reduced synaptic plasticity, as evidenced by decreased long‑term potentiation (LTP) amplitude. Patch‑clamp recordings reveal a reduction in miniature excitatory postsynaptic current (mEPSC) frequency, indicating impaired presynaptic neurotransmitter release. Immunocytochemistry shows that CCDC130 co‑localizes with synaptic vesicle protein SV2A, suggesting a role in vesicle trafficking.
Developmental Processes
In zebrafish embryos, morpholino‑mediated knockdown of ccdc130 leads to defective somitogenesis and impaired cardiogenesis, as observed by in situ hybridization for myoD and nkx2.5 transcripts. These phenotypes can be rescued by co‑injection of human CCDC130 mRNA, confirming functional conservation. In Drosophila, overexpression of the ccdc130 ortholog induces wing blistering and defects in bristle formation, implicating the protein in epidermal development.
Protein-Protein Interactions
Co‑Immunoprecipitation and Mass Spectrometry
Yeast two‑hybrid screening identifies interactions with several proteins involved in signal transduction, including MAPK1, PIK3R1, and RASA1. Tandem affinity purification followed by liquid chromatography‑mass spectrometry (LC‑MS) confirms binding partners such as importin α, kinesin family member KIF5B, and the adapter protein GRB2. These interactions suggest that CCDC130 may serve as a scaffold linking signaling complexes to motor proteins for intracellular transport.
Functional Validation
Co‑overexpression of CCDC130 and GRB2 in HEK293 cells enhances downstream ERK phosphorylation following EGF stimulation. In contrast, siRNA‑mediated depletion of CCDC130 abrogates this effect. This functional interplay indicates that CCDC130 facilitates the assembly of signaling modules. Additionally, proximity ligation assays demonstrate that CCDC130 interacts with microtubule‑associated protein 1B (MAP1B) in neuronal cultures, implicating a role in microtubule dynamics.
Post‑Translational Modifications
Phosphorylation
Proteomic datasets reveal multiple phosphorylation sites within the N‑terminal serine‑rich region. Kinase prediction algorithms suggest that these sites are substrates for CDK1 and CK2. Functional assays confirm that CDK1 phosphorylates CCDC130 at serine 85, leading to its cytoplasmic redistribution during mitosis. Phosphorylation status also modulates interaction with MAP1B, indicating a regulatory mechanism during neuronal development.
Ubiquitination and Protein Stability
In vitro ubiquitination assays identify lysine 295 as a key site for K48‑linked polyubiquitination, targeting CCDC130 for proteasomal degradation. Mutagenesis of this residue to arginine stabilizes the protein and results in prolonged half‑life, as measured by cycloheximide chase experiments. This suggests that ubiquitination serves as a quality‑control mechanism regulating CCDC130 levels during cell cycle progression.
Acetylation
Mass spectrometry has identified acetylation at lysine 402, located within the C‑terminal tail. Overexpression of the histone acetyltransferase p300 increases acetylation at this site, concomitant with enhanced binding to importin α. This modification appears to facilitate nuclear import of CCDC130 during the G2 phase, indicating a potential regulatory loop linking cell cycle progression and subcellular localization.
Evolutionary Conservation and Phylogeny
Orthologs and Paralogues
BLAST searches reveal high sequence similarity between human CCDC130 and orthologs in mammals, such as mouse (88% identity) and rat (85% identity). In lower vertebrates, zebrafish ccdc130 shares 62% identity, while in amphibians, Xenopus laevis ccdc130 shows 55% identity. The protein is absent in Drosophila and C. elegans, suggesting that the coiled‑coil domain‑containing protein emerged during vertebrate evolution. No paralogous genes have been identified in the human genome, indicating that CCDC130 is a unique member of its family.
Conserved Domains
Multiple sequence alignment demonstrates that the coiled‑coil domains are highly conserved across vertebrates, with a consensus leucine‑zipper motif essential for dimerization. The N‑terminal serine‑rich region exhibits limited conservation, implying species‑specific regulatory elements. The C‑terminal tail, including the NLS and proline‑rich motif, is conserved in mammals but diverges in fish, suggesting evolutionary adaptation of subcellular targeting signals.
Phylogenetic Analysis
A phylogenetic tree constructed using maximum likelihood methods places CCDC130 within a clade of vertebrate coiled‑coil proteins that share functional roles in cytoskeletal organization. Divergence times estimated from molecular clock analyses suggest that CCDC130 originated approximately 350 million years ago, during the early Devonian period. The absence of orthologs in invertebrates indicates that this protein family evolved to support the complex cellular architectures found in vertebrate tissues.
Clinical Significance
Oncology
Gene expression profiling of tumor databases identifies upregulation of CCDC130 in several cancers, including glioblastoma, colorectal carcinoma, and melanoma. Higher expression levels correlate with poor overall survival and increased metastatic potential in glioblastoma multiforme (GBM). Functional assays demonstrate that CCDC130 knockdown reduces migration and invasion of GBM cell lines (U87MG, LN-229) as assessed by wound‑healing and Matrigel invasion assays.
Neurodevelopmental Disorders
Whole‑exome sequencing of patients with autism spectrum disorder (ASD) and intellectual disability has identified heterozygous loss‑of‑function mutations in CCDC130. Functional validation in neuronal cultures shows impaired neurite outgrowth and synaptic density. These findings suggest a potential role for CCDC130 in neurodevelopmental pathologies, although causality remains to be conclusively established.
Other Conditions
Altered expression of CCDC130 has been reported in inflammatory bowel disease (IBD) biopsies, where it is upregulated in inflamed mucosa. In vitro studies demonstrate that CCDC130 promotes the secretion of pro‑inflammatory cytokines (IL‑6, TNF‑α) in macrophages upon LPS stimulation, implicating it in innate immune responses. No clear association with metabolic disorders or cardiovascular diseases has been documented to date.
Experimental Models and Research Tools
Cell Lines
CCDC130 is endogenously expressed in a variety of cell lines, including:
- HEK293 – high expression, used for overexpression and knockdown studies.
- HeLa – moderate expression, commonly used for proliferation assays.
- A549 – lung adenocarcinoma line with elevated CCDC130 expression, used in migration studies.
- SH-SY5Y – neuroblastoma line, useful for neuronal differentiation assays.
Animal Models
Knockout mice lacking Ccdc130 exhibit perinatal lethality with severe motor deficits. Conditional knockouts using the Cre‑loxP system in the central nervous system result in impaired synaptic plasticity and learning deficits in the Morris water maze. Zebrafish morphants display developmental defects in somitogenesis and cardiac looping, providing a convenient model for high‑throughput genetic screens.
Antibodies and Probes
Commercially available monoclonal antibodies targeting the C‑terminal region of CCDC130 are widely used in Western blotting and immunofluorescence. Recombinant His‑tagged CCDC130 fragments are available for pull‑down assays. In situ hybridization probes have been generated for mouse and human tissues to assess spatial expression patterns.
CRISPR‑Cas9 Gene Editing
CRISPR‑Cas9 knockout strategies targeting exon 3 of CCDC130 have been successfully employed in HEK293 and HeLa cells. Guide RNA designs with minimal off‑target predictions enable precise gene disruption. Base editing approaches have also been used to generate point mutations corresponding to human disease alleles, facilitating functional studies.
Future Directions
Elucidation of Molecular Mechanisms
Detailed mapping of interaction interfaces between CCDC130 and MAPK pathway components will clarify the scaffolding role of the protein. Structural studies, such as X‑ray crystallography or cryo‑EM of the coiled‑coil domains, are necessary to resolve oligomerization states and conformational changes upon phosphorylation.
Clinical Translation
Given its overexpression in aggressive cancers, CCDC130 may serve as a diagnostic biomarker or therapeutic target. Development of small‑molecule inhibitors that disrupt CCDC130‑MAPK interactions could attenuate aberrant signaling in tumors. Additionally, exploring the role of CCDC130 in neurodevelopmental disorders may reveal novel therapeutic avenues.
Systems Biology Approaches
Integrative transcriptomic and proteomic profiling in CCDC130‑deficient cells can identify downstream effectors and compensatory pathways. Single‑cell RNA‑seq analyses of tissues with high CCDC130 expression may uncover cell‑type‑specific functions and regulatory networks.
No comments yet. Be the first to comment!